CAN SLIM Investing: Rules and Risks
Table of Contents
CAN SLIM investing combines earnings growth, business developments, price leadership and market conditions in a stock-selection framework. Its practical appeal is a structured research process. The difficulty is turning seven letters into evidence available on a particular date, then deciding whether a candidate also meets an entry and risk-management plan.
A stock can pass several financial filters while its business catalyst, institutional support or chart interpretation remains uncertain. This guide explains the criteria, builds a preliminary screen and shows why a passing result does not establish a good investment. The examples concern U.S. equities; historical company figures are dated, and invented prices are explicitly hypothetical.
What Is CAN SLIM?
William J. O’Neil’s CAN SLIM framework joins company analysis with price, volume and broad-market assessment. Finding candidates, deciding when to enter and managing an existing position are separate tasks. A database filter addresses only part of that process.
O’Neil described the seven themes in his own June 2003 article. His publisher’s page for the 2009 fourth edition of How to Make Money in Stocks also lists the factors and separate chapters on selling. The summary below follows those themes; numerical examples later in this guide are labeled by source and version. [1] [2]
The Seven CAN SLIM Criteria
Use the letters to organize a research file. The final column suggests evidence to collect; it is a practical documentation guide rather than a claim that each theme has one universal pass/fail formula.
| Letter | Theme | Evidence to document |
|---|---|---|
| C | Current quarterly earnings | Comparable year-over-year EPS, accounting basis and report date. |
| A | Annual earnings growth | Several years of earnings, their consistency and unusual items. |
| N | New developments and price highs | A business catalyst and the context of a potential price breakout. |
| S | Share supply and trading demand | Share availability, issuance or repurchases, and price/volume behavior. |
| L | Leadership | Comparative price performance and relevant industry peers. |
| I | Institutional sponsorship | Identified institutional holders, reporting periods and changes. |
| M | Market direction | Broad-index price/volume evidence and a dated exposure decision. |
The framework blends parts of fundamental analysis with market behavior. The evidence differs by letter: reported EPS is a number, while the significance of a new product or the quality of a developing chart pattern requires interpretation.
Keep Method Versions Distinct
IBD’s buying infographic, copyrighted 2021, gives useful numerical reference points: at least 25% latest-quarter earnings growth, 25% earnings growth over the last three years, 25% latest-quarter sales growth and 17% ROE. It also considers a new industry-leading product or service. Those are that dated provider checklist’s guidelines, rather than proof that every edition and screen uses identical definitions. [3]
AAII, for example, describes three CAN SLIM screen versions, including one that removes its earlier share-float limit and another based on the revised third edition. A result labeled “CAN SLIM” therefore needs its actual rules attached before it can be compared with another result. [10]
Measure Earnings Growth on a Comparable Basis
For a positive prior-year base, compare the latest reported quarter with the corresponding quarter one year earlier. This avoids treating a normal seasonal change between consecutive quarters as annual growth. Specify basic or diluted earnings per share, GAAP or a defined adjusted measure, and consistent stock-split treatment.
A negative base needs separate treatment. Suppose a fictional company moves from a $0.20 loss per share to a $0.10 profit. EPS improves by $0.30, but the conventional calculation gives [$0.10 − (−$0.20)] / (−$0.20) × 100 = −150%. Label this a turnaround; do not read that quotient as ordinary positive-base growth. A zero base is undefined, and a tiny positive base can produce a large percentage from a small dollar change.
Annual growth needs a convention too. A compound annual growth rate, or CAGR, compares endpoints over a specified number of intervals:
For hypothetical annual EPS of $1.00, $1.20, $1.60 and $2.00, the three-year CAGR is [(2 / 1)1/3 − 1] × 100 = 25.99%. Yet the first year’s increase is only (1.20 − 1.00) / 1.00 × 100 = 20%. A 25% CAGR filter and a requirement for 25% growth in every year select different companies. Inspect the intervening years instead of assuming a smooth path.
A Historical EPS Screening Example
Consider two separate historical earnings releases, using GAAP diluted EPS and the comparison figures presented in each release. NVIDIA’s per-share figures below already reflect its ten-for-one split. These observations illustrate the quarterly-growth test; they do not reconstruct either company’s complete CAN SLIM eligibility. [5] [6]
| Company and release | Quarter / year-earlier EPS | Calculation | At least 25%? |
|---|---|---|---|
| NVIDIA, February 26, 2025 | Q4 FY2025: $0.89 / $0.49 | (0.89 − 0.49) / 0.49 × 100 = 81.63% | Yes, for this condition only |
| Microsoft, July 30, 2025 | Q4 FY2025: $3.65 / $2.95 | (3.65 − 2.95) / 2.95 × 100 = 23.73% | No, under this threshold |
Microsoft’s exclusion under a particular growth gate says what that rule selects; it does not establish that the business or stock is unattractive. Likewise, NVIDIA’s passing result leaves the other criteria, entry price and subsequent outcome untested.
Accounting definitions can change the answer. NVIDIA reported the same $0.89 current EPS on its non-GAAP basis, but the comparable prior-year figure was $0.52. That growth calculation is (0.89 − 0.52) / 0.52 × 100 = 71.15%, rather than 81.63%. Keep both periods on the chosen basis. [5]
Respect when information became available. NVIDIA’s quarter ended January 26, 2025, and Microsoft’s ended June 30, 2025. Their cited results were released February 26 and July 30, respectively. A historical screen cannot use those releases at quarter-end. Record publication time and use an execution convention that occurs after the information is public; do not assign a trade at an earlier closing price.
How to Build a Preliminary CAN SLIM Screen
Start with a documented universe of U.S.-listed operating-company common stocks and a fixed observation time. Record any liquidity, price or industry exclusions. The following is an illustrative implementation of the financial shortlist, using the dated IBD reference levels. Its GAAP, CAGR and ROE calculation choices are specified here for reproducibility; the infographic alone does not define them.
| Test | Illustrative rule | Required data convention |
|---|---|---|
| Quarterly EPS | At least 25% year-over-year growth | Reported GAAP diluted EPS; both quarters positive; matching split basis |
| Quarterly sales | At least 25% year-over-year growth | Matching consolidated revenue periods and units; positive base |
| Annual EPS | At least 25% three-year CAGR | Four annual GAAP diluted EPS observations, all positive; inspect each year separately |
| ROE | At least 17% | Latest annual common-share earnings / average beginning-and-ending common equity; positive average equity |
These filters create a candidate list. A different adjusted-earnings definition, annual-growth rule or equity averaging method can change it. Trace the inputs to filings and reconciliations, and examine unusual gains, acquisitions or buybacks. A high return on equity can reflect a smaller equity denominator as well as operating performance.
Save each input’s value, fiscal period, publication date, source and calculation. Keep pass, fail and unresolved as separate states. Missing EPS, unavailable historical ownership data or noncomparable accounts are not zeroes and should not silently become passing observations. The field-audit approach in our stock tear sheets guide helps keep dates and definitions aligned.
Complete the Manual Evidence Checklist
For each survivor, add dated notes covering the remaining themes and entry conditions. Specify what evidence would satisfy each judgment before looking at subsequent returns.
- N — Identify the development. Name the product, service, management change or other catalyst, cite its announcement and explain why it could matter economically. A marketing claim is not evidence of realized profitable growth.
- S — Examine supply and demand together. Record share changes and the chosen float definition. Inspect trading volume alongside price; turnover alone does not identify who bought or prove lasting institutional demand.
- L — Specify comparative strength. State the comparison universe, observation date, return window and price or total-return basis. A simple return rank is a disclosed proxy; do not label it IBD’s proprietary rating.
- I — Date the ownership evidence. Identify holders and compare matching reporting periods. SEC Form 13F reports are generally due within 45 days after quarter-end, with calendar adjustments, so they cannot establish real-time buying. [7]
- M — Write the market assessment. Identify the broad indexes, price/volume evidence and exposure decision. Record what would invalidate it. O’Neil’s 2003 discussion explicitly acknowledges that confirmed rally attempts can fail. [1]
Then evaluate the chart entry separately. IBD’s dated buying guide calls for a high-volume breakout from a base and an entry within 5% of its buy point. A base is a period of price consolidation; the buy point, often called a pivot, is the method’s chart-based entry reference. Merely being near a 52-week high does not establish that the whole entry setup is valid. [3]
CAN SLIM Sell Rules and Execution Risk
Write the exit plan before entering. In IBD/MarketSmith’s 2023 Q4 Stock Guide, the defensive rule is to cut losses no later than 7%–8% below the price actually paid. Its profit-taking discussion uses a 20%–25% zone above the chart’s pivot for most stocks, while allowing additional rules for managing some strong winners. This is a bounded summary of that dated guidance, not every sell or hold exception across editions. [4]
Consider a hypothetical $100 pivot and a $104 actual purchase, with no fees. The two reference prices produce different calculations:
8% below the purchase: $104 × (1 − 0.08) = $95.68.
20%–25% above the pivot: $100 × 1.20 to $100 × 1.25 = $120–$125.
At $120, the actual purchase gain is ($120 − $104) / $104 × 100 = 15.38%. Calling it a 20% return on the amount paid would use the wrong denominator.
A planned loss threshold cannot guarantee that outcome. The SEC explains that a stop order becomes a market order and may execute well beyond its trigger; a stop-limit order may remain unfilled. If the hypothetical stock gaps down and the assumed sale fills at $90, the loss is ($104 − $90) / $104 × 100 = 13.46%, before costs. [8]
Position limits, total portfolio exposure and correlated holdings therefore matter alongside a per-stock exit. Repeated small losses, failed breakouts and earnings gaps can damage a portfolio even when the research process is followed consistently.
CAN SLIM vs Momentum and Quality Screens
These approaches can select overlapping stocks, but their required evidence differs. Comparing their definitions is more useful than assuming one label implies another.
| Approach | Main selection emphasis | What still needs specification |
|---|---|---|
| CAN SLIM | Earnings, developments, leadership, sponsorship and market context | Method version, manual judgments, entries, exits and exposure |
| Momentum investing | Comparative past-return strength in a defined implementation | Return window, universe, rebalancing and portfolio rules |
| Quality screen | Profitability, earnings stability and financial strength under a chosen definition | Metrics, weighting, exclusions and portfolio rules |
For a concrete quality example, MSCI uses high ROE, stable year-over-year earnings growth and low financial leverage. Rapid growth in the latest quarter is a different emphasis from earnings stability. Neither description alone establishes a cheap valuation or superior future return. [9]
Price relative strength is also different from the Relative Strength Index. Comparative strength evaluates performance against other securities or a benchmark. RSI summarizes the balance of a security’s own recent upward and downward price changes. An RSI reading is not a peer percentile or an IBD RS Rating.
What Does the Performance Evidence Establish?
First distinguish how a method was developed from how it was tested. McGraw Hill describes O’Neil’s research in terms of past market winners. Looking backward at winners can generate useful hypotheses, but it does not show how often the same characteristics appeared in stocks that later failed, or what a contemporaneous portfolio would have earned. That is an inference about research design, not a conclusion that the method cannot work. [2]
Next identify the implementation behind any advertised record. AAII’s screen variants differ. A historical 2020 CAN SLIM Select Growth Fund filing describes a managed portfolio that sought to imitate, but did not fully replicate, a weekly stock list and could hold substantial cash. Its portfolio choices and expenses belong to its own results; they are not a return for every seven-letter checklist. [10] [12]
Before treating a backtest as investable evidence, establish:
- Point-in-time inputs: financial reports, estimates and ownership information available before each decision, without later restatements or future constituent lists leaking backward.
- A complete universe: include delisted and failed firms, with appropriate delisting outcomes, rather than only today’s survivors.
- Complete portfolio rules: entry and exit timing, position weights, cash, missing data, dividends, corporate actions and failed trades.
- Realistic frictions: spreads, slippage, market impact, fees, turnover and relevant taxes; a nominal stop price is not a guaranteed fill.
- A fair comparison: total returns, risk, drawdowns, exposures and the same evaluation period, including adverse regimes.
- Protection against tuning: disclose variants tried and assess evidence beyond the data used to select the rules.
Bailey and coauthors explain how repeated historical strategy testing can select noise rather than a persistent signal. Their paper concerns backtest methodology; it does not independently test CAN SLIM. No full-method backtest or achievable excess-return estimate is established in this guide. [11]
Common Mistakes
- Treating a shortlist as a buy list. Resolve the qualitative evidence, market assessment, entry and portfolio constraints separately.
- Substituting forecast growth for reported growth. Analyst estimates and management guidance need separate labels and observation dates.
- Ignoring the EPS base. Losses, zeroes, small denominators, split changes and inconsistent adjustments can distort comparisons.
- Replacing every difficult criterion with an arbitrary filter. Record proxies and author choices; preserve unresolved judgments.
- Confusing a high price with an expensive valuation. A new high is a price observation; valuation needs its own analysis.
- Using future information or perfect fills. Reporting lags and execution belong in the evidence, not outside the model.
Limitations of CAN SLIM Investing
Growth can slow, catalysts can disappoint and market confirmations can fail. Chart and sponsorship judgments may differ between analysts. Following a documented rule does not guarantee a profit or limit realized losses to the planned percentage.
The process also takes time and suitable data. Historical point-in-time records and proprietary ratings may be unavailable, while a convenient substitute can materially change the strategy. Concentration in similar growth companies, repeated trading costs and missed rallies while holding cash can affect results. The framework helps make decisions inspectable; suitability and the price paid still require independent judgment.
Frequently Asked Questions
Sources and Methodology
- William J. O’Neil: The Big Picture: How to Determine the Stock Market’s Direction, June 2003. Author’s seven-factor summary and historical market-assessment explanation.
- McGraw Hill: How to Make Money in Stocks, Fourth Edition, May 18, 2009. Public publisher metadata, overview and displayed contents; not a full-book source read.
- IBD’s 3-Step Buying Checklist, copyright 2021. Dated fundamentals and entry guidelines.
- IBD/MarketSmith: Stock Guide 2023 Q4, printed pages 7–8. Purchase-based loss rule and pivot-based profit zone.
- NVIDIA: Fourth Quarter and Fiscal 2025 Results, February 26, 2025. EPS comparisons and split-adjustment note.
- Microsoft: Earnings Release FY25 Q4, July 30, 2025. GAAP quarterly EPS comparisons.
- SEC staff: Frequently Asked Questions About Form 13F, timing discussion. Quarterly reporting lag and deadline adjustments.
- SEC Investor.gov: Stop, Stop-Limit, and Trailing Stop Orders. Execution and nonexecution risks.
- MSCI: Quality Indexes. Provider’s stated selection variables.
- AAII: CAN SLIM: Seven Attributes That Set Market Leaders Apart, March 26, 2026. Evidence of AAII’s distinct screen versions, rather than verification of advertised returns.
- Bailey, Borwein, López de Prado and Zhu: The Probability of Backtest Overfitting, revised February 27, 2015; abstract and introduction. General repeated-testing caveat.
- CAN SLIM Select Growth Fund: historical 2020 SEC filing, Principal Investment Strategies. One managed implementation; no current product recommendation.
Sources accessed November 15, 2026. The financial shortlist is an explicitly specified illustration, not an official CAN SLIM certification or proprietary IBD screen. Company releases establish dated reported inputs; the hypothetical EPS and price examples establish arithmetic, not trading results.
Disclaimer
This article is for educational and informational purposes only and does not constitute investment advice. Mentioned securities are examples, not recommendations. Screening conditions, historical growth and planned exits do not guarantee future performance or protection from loss. Consider your circumstances and consult a qualified financial professional before making investment decisions.
